Page last updated: 2024-12-08
cyhalofop-butyl
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
cyhalofop-butyl: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 180089 |
CHEMBL ID | 1900438 |
CHEBI ID | 81863 |
SCHEMBL ID | 56020 |
MeSH ID | M0486334 |
Synonyms (48)
Synonym |
---|
cyhalofop-butyl |
122008-85-9 |
cyhalofop-butyl [iso] |
xde 537 |
NCGC00168299-01 |
clincher |
hsdb 7272 |
propanoic acid, 2-(4-(4-cyano-2-fluorophenoxy)phenoxy)-, butyl ester, (2r)- |
butyl (2r)-2-[4-(4-cyano-2-fluorophenoxy)phenoxy]propanoate |
butyl (2r)-2-[4-(4-cyano-2-fluoranyl-phenoxy)phenoxy]propanoate |
(2r)-2-[4-(4-cyano-2-fluorophenoxy)phenoxy]propanoic acid butyl ester |
A804822 |
NCGC00168299-02 |
(2r)-2-(4-(4-cyano-2-fluorophenoxy)-phenoxy)propanic acid butylester |
ccris 9267 |
unii-18hgv9oc6g |
(r)-2-[4-(4-cyano-2-fluorophenoxy)phenoxy]propionic acid butyl ester |
C2417 |
butyl (r)-2-[4-(4-cyano-2-fluorophenoxy)phenoxy]propionate |
cyhalofop butyl |
C18607 |
dtxsid1034503 , |
cas-122008-85-9 |
tox21_301029 |
dtxcid9014503 |
NCGC00254931-01 |
18hgv9oc6g , |
AKOS015889006 |
SCHEMBL56020 |
cyhalofop butyl ester |
(2r)-2-(4-(4-cyano-2-fluorophenoxy)phenoxy)propanoic acid butyl ester |
cyhalofop-butyl [mi] |
xde-537 |
cyhalofop-butyl [hsdb] |
CHEBI:81863 , |
CHEMBL1900438 |
clincher; clincher ca;xde 537 |
J-004751 |
(r)-butyl 2-(4-(4-cyano-2-fluorophenoxy)phenoxy)propanoate |
propanoic acid, 2-[4-(4-cyano-2-fluorophenoxy)phenoxy]-, butyl ester, (2r)- |
cyhalofop-butyl, pestanal(r), analytical standard |
mfcd01631151 |
cyhalofop-butyl 10 microg/ml in cyclohexane |
Q27155630 |
xde537 |
BS-21239 |
CS-0012875 |
HY-B0861 |
Research Excerpts
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
" Our results demonstrated that cyhalofop-butyl was highly toxic to zebrafish embryos, with concentration-dependent negative effects in embryonic development." | ( Cyhalofop-butyl has the potential to induce developmental toxicity, oxidative stress and apoptosis in early life stage of zebrafish (Danio rerio). Chai, T; Mu, X; Qiu, L; Wang, C; Wang, K; Yang, Y; Zhu, L, 2015) | 2.15 |
Dosage Studied
HFFD3 was highly resistant to cyhalofop-butyl and exhibited cross-resistance to metamifop, fenoxaprop-P-ethyl. Whole-plant dose-response experiments showed that the resistance index (RI) of these R? RR, and RRR populations to cy Halfop-Butyl ranged from 2 to 4.
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (13)
Potency Measurements
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
SMAD family member 2 | Homo sapiens (human) | Potency | 27.3707 | 0.1737 | 34.3047 | 61.8120 | AID1346859 |
SMAD family member 3 | Homo sapiens (human) | Potency | 27.3707 | 0.1737 | 34.3047 | 61.8120 | AID1346859 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 24.1881 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 24.7156 | 0.0002 | 21.2231 | 8,912.5098 | AID588516; AID743036; AID743054; AID743063 |
progesterone receptor | Homo sapiens (human) | Potency | 54.1504 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 17.7296 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 27.1395 | 0.0015 | 30.6073 | 15,848.9004 | AID1259403 |
farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 31.6228 | 0.3758 | 27.4851 | 61.6524 | AID588527 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 19.3770 | 0.0002 | 29.3054 | 16,493.5996 | AID743075 |
peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 17.2698 | 0.0010 | 24.5048 | 61.6448 | AID743215 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 15.8489 | 0.0237 | 23.2282 | 63.5986 | AID588541 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 17.8660 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895; AID1259385; AID1259395 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 4.3013 | 0.0006 | 27.2152 | 1,122.0200 | AID743202 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (42)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (9.52) | 29.6817 |
2010's | 19 (45.24) | 24.3611 |
2020's | 19 (45.24) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 36.51
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (36.51) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (2.38%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 41 (97.62%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |